FDA Approves Bristol Myers’ Non-Small Cell Lung Cancer Drug
Augtyro was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Augtyro was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Women are less likely to be given bystander CPR than men in public places, but in private spaces, older people are less likely to be given CPR, according to research presented at the European Emergency Medicine Congress.
Despite advancements, a Michigan Medicine study finds that the death rate for pulmonary embolism remains high and unchanged in recent years—more often killing men, Black patients, and those from rural areas.
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking FDA approval of an investigational single-tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
A modeling study suggests that continuing anticoagulation therapy indefinitely, which is recommended in all patients with a first unprovoked venous thromboembolism, has little chance of improving life expectancy and is unlikely to ever be cost-effective.
Retained and excessive secretions can lead to disorders like atelectasis but therapies like Percussionaire's IPV therapy—recently acquired by Sentec—can improve patient outcomes.
LUNGevity Foundation has launched an Early Lung Cancer Center to accelerate the development and broad adoption of early detection and treatment options.